BlackRock Fund Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

BlackRock Fund Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$116K	Buy	194 +6	+3%	+$6.34K	﹤0.01%	3574
2016 Q3	$213K	Hold	188	–	–	﹤0.01%	3430
2016 Q2	$206K	Buy	188 +24	+15%	+$30.1K	﹤0.01%	3443
2016 Q1	$211K	Sell	164 -13	-7%	-$18.5K	﹤0.01%	3444
2015 Q4	$435K	Buy	177 +6	+4%	+$9.21K	﹤0.01%	3301
2015 Q3	$189K	Sell	171 -4	-2%	-$4.63K	﹤0.01%	3483
2015 Q2	$176K	Sell	175 -1,334	-88%	-$1.44M	﹤0.01%	3574
2015 Q1	$1.53M	Sell	1,509 -23	-2%	-$75.9K	﹤0.01%	3176
2014 Q4	$5.11M	Buy	1,532 +289	+23%	+$886K	﹤0.01%	2861
2014 Q3	$3.6M	Sell	1,243 -51	-4%	-$169K	﹤0.01%	2937
2014 Q2	$4.92M	Buy	+1,294	New	+$4.87M	﹤0.01%	2840

Other funds holding NBSE

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

SIP

Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

BlackRock Fund Advisors's NBSE Position: Q4 2016 in Review

BlackRock Fund Advisors increased its NeuBase Therapeutics, Inc. Common Stock (NBSE) stake by 3.2% in Q4 2016, buying an estimated $6.34K and bringing the position to 194 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #3574.

BlackRock Fund Advisors first reported a position in NBSE in Q2 2014 and has held it in 11 quarters since. The position peaked at $5.11M in Q4 2014. 49 funds tracked by Wall St. Rank hold NBSE as of Q4 2016.

BlackRock Fund Advisors held 194 shares of NeuBase Therapeutics, Inc. Common Stock worth $116K as of Q4 2016.
BlackRock Fund Advisors bought 6 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $6.34K.
NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3574 holding.
BlackRock Fund Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 11 quarters since.
BlackRock Fund Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $5.11M in Q4 2014.
49 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.